Facebook
Twitter
LinkedIn
Forward
Obesity Medicine 2023 - Spring Obesity Summit
|
This session covers new AASLD guidelines for screening, disease associations, diagnosis, and treatments.CME/CE Expiration Date: 10/27/26
|
Treatment of people with unhealthy weight has typically focused on those with obesity or in those with BMI ≥ 27 with existing comorbidities; however, evidence indicates that the negative effects of
|
Obesity is a complex phenotype reflecting the interactions of numerous genes that have been “selected” for in service of reproductive integrity with modern environments.
|
Intermittent Fasting (IF) as a means of dietary modification has gained popularity among individuals with obesity as a means of achieving weight loss.
|
This session will review the relationship and underlying mechanisms between obesity and cardiovascular disease with attention to the individual variability between BMI and CV risk.
|
The session will begin by providing a general overview of the prevalence and epidemiology of nonalcoholic fatty liver disease.
|
This session will focus on the management of non-alcoholic fatty liver disease (NAFLD) with a particular emphasis on the role of GLP-1 agonists and SGLT-2 inhibitors in treating this condition.
|
One of the limitations of BMI is that it fails to account for either body composition or body fat distribution.
|
Recorded during Overcoming Obesity 2022. CME/CE Expiration Date: 11/1/25
|